Scholars Central

Conference abstractPublished 8 Oct 2018

Anti-GnRH receptor monoclonal antibodies are long acting biosimilar GnRH antagonists

Authors: Song-Nan Chow, Gregory Lee, Chin-Hsiang Chien

National Taiwan University Hospital, Taiwan; Min-Sheng General Hospital, Taiwan; University of British Columbia, Canada; OncoLock Co.Ltd, Taiwan

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

Monoclonal antibodies were generated against a synthetic peptide corresponding to N1-29 sequence located in the extracellular domain of human GnRH receptor. Among the fourteen established monoclonal antibodies GHR103 and GHR106 were shown to have the highest affinity (Kdâ??2x10-9 M) to the synthetic peptide as well as to the native GnRH receptor in cancer cell extract as well as those from the anterior pituitary in humans. Through immunoglobulin gene analysis, both GHR103 and GHR106 were shown to have identical DNA sequences in both heavy and light chains of IgG1 subclass. GHR106 was shown to be highly specific to N1-29 peptides derived from GnRH receptor of human and money, but not to that from mouse. Immunohistochemical studies were performed with as many as 30 different cancer cell lines and were found to positively stain more than 80% of cases, irrespective of their tissue origins. Consistent results were obtained with other assays such as Western Blot, indirect immunofluorescence and RT-PCR. Similar to GnRH decapeptide antagonist, Antide, GHR106 was shown to induce apoptosis and inhibit cell proliferation to culturing cancer cells by TUNEL and MTT assays, respectively. Furthermore, GHR106 was shown to induce lysis of cancer cells in culture through complement-dependent cytotoxicity reactions (CDC) which are absent with GnRH peptide analogs. Humanized forms of GHR106 (hGHR106) were generated and found to be bioequivalent to murine GHR106 (mGHR106) as well as to GnRH antagonist, Antide in terms of their respective binding affinity and biological properties. Due to widespread expressions of GnRH receptor among various human cancer, hGHR106 can be bioequivalent alternative to GnRH decapeptide analogs and can serve as the antibody-based anti-cancer drugs of much longer half-life as compared to that of GnRH decapeptide analogs (days vs. hrs.). Furthermore, humanized GHR106 can be long-acting substitute to GnRH decapeptide analog for numerous gynecological indications in fertility regulations and women health.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

Similar by topic

More from this journal

The newest in Gynecology & Obstetrics.

All its articles

Conferences in this field

Upcoming conferences in this field.

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalGynecology & Obstetrics
  • SubjectReproductive Medicine & Gynaecology
  • BylineArticles whose byline prints “Song-Nan Chow”
  • BylineArticles whose byline prints “Gregory Lee”
  • BylineArticles whose byline prints “Chin-Hsiang Chien”

For authors and organisers

Publish, present and keep up with your field

Find the right journal for your paper and submit your manuscript.

Photo: Pexels